Abstract
Myocardial Ischemia/Reperfusion (I/R) induced injury has widespread detrimental effects partially negating the benefits obtained from early revascularization in Acute Myocardial Infarction. Various complex mechanisms contribute to I/R injury and different agents targeting those specific mechanisms are being studied. Despite continued research and widespread interest, none of them have become incorporated into everyday practice. The TRPV1 (transient receptor potential vanilloid 1) channel is a non selective cation channel predominantly expressed in sensory neurons with the nerve fibers innervating the heart and blood vessels. Multiple studies have demonstrated the importance of the activation of TRPV1 and subsequent release of sensory neurotransmitters in cardioprotection. This review focuses on the role of TRPV1 in prevention of cardiac I/R injury, the work that has been done so far and future implications for TRPV1 agonists as cardioprotective agents.
Keywords: Agonist, cardioprotection, Ischemia/Reperfusion, myocardium, TRPV1.
Cardiovascular & Hematological Disorders-Drug Targets
Title:Myocardial Ischemia/Reperfusion Injury: Potential of TRPV1 Agonists as Cardioprotective Agents
Volume: 14 Issue: 1
Author(s): Praveen Vemula, Bikki Gautam, George S. Abela and Donna H. Wang
Affiliation:
Keywords: Agonist, cardioprotection, Ischemia/Reperfusion, myocardium, TRPV1.
Abstract: Myocardial Ischemia/Reperfusion (I/R) induced injury has widespread detrimental effects partially negating the benefits obtained from early revascularization in Acute Myocardial Infarction. Various complex mechanisms contribute to I/R injury and different agents targeting those specific mechanisms are being studied. Despite continued research and widespread interest, none of them have become incorporated into everyday practice. The TRPV1 (transient receptor potential vanilloid 1) channel is a non selective cation channel predominantly expressed in sensory neurons with the nerve fibers innervating the heart and blood vessels. Multiple studies have demonstrated the importance of the activation of TRPV1 and subsequent release of sensory neurotransmitters in cardioprotection. This review focuses on the role of TRPV1 in prevention of cardiac I/R injury, the work that has been done so far and future implications for TRPV1 agonists as cardioprotective agents.
Export Options
About this article
Cite this article as:
Vemula Praveen, Gautam Bikki, Abela S. George and Wang H. Donna, Myocardial Ischemia/Reperfusion Injury: Potential of TRPV1 Agonists as Cardioprotective Agents, Cardiovascular & Hematological Disorders-Drug Targets 2014; 14 (1) . https://dx.doi.org/10.2174/1871529X13666131129103759
DOI https://dx.doi.org/10.2174/1871529X13666131129103759 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
FoxO Transcription Factors and Regenerative Pathways in Diabetes Mellitus
Current Neurovascular Research Flavonoids in Atherosclerosis: An Overview of Their Mechanisms of Action
Current Medicinal Chemistry Cardiac Applications for Human Pluripotent Stem Cells
Current Pharmaceutical Design Cardiac Metabolism in Myocardial Ischemia
Current Pharmaceutical Design Targeting IL-17 and IL-23 in Immune Mediated Renal Disease
Current Medicinal Chemistry B-Type Natriuretic Peptide for Diagnosis and Therapy
Recent Patents on Cardiovascular Drug Discovery Targeting Mitochondrial Oxidative Stress Through Lipoic Acid Synthase: A Novel Strategy to Manage Diabetic Cardiovascular Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry Pharmacological Manipulation of Peripheral Vascular Resistance in Single Ventricle Patients (Stages I, II, and III of Palliation)
Current Vascular Pharmacology Malignant Hypertension: A Rare Problem or is it Underdiagnosed?
Current Vascular Pharmacology Targeting Endothelial Progenitor Cells in Cancer as a Novel Biomarker and Anti-Angiogenic Therapy
Current Stem Cell Research & Therapy Novel Concept in the Mechanism of Injury and Protection of Gastric Mucosa: Role of Renin-Angiotensin System and Active Metabolites of Angiotensin
Current Medicinal Chemistry Antiarrhythmic Therapy on Prevention of Postoperative Atrial Fibrillation in Patients After Heart Surgery
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Acute Respiratory Failure in Obstetric Patients
Current Women`s Health Reviews Interactions Between Plasma Proteins and Naturally Occurring Polyphenols
Current Drug Metabolism Modulation of Inflammatory Response Improves Myocardial Infarct Healing in Rats
Current Pharmaceutical Design GP IIb / IIIa Blockade in Elective Percutaneous Coronary Intervention
Current Pharmaceutical Design Diabetic Heart and the Cardiovascular Surgeon
Cardiovascular & Hematological Disorders-Drug Targets Endotoxin, TLR4 Signaling and Vascular Inflammation: Potential Therapeutic Targets in Cardiovascular Disease
Current Pharmaceutical Design Meet Our Editorial Board Member
Current Pharmaceutical Biotechnology Role of Stromal-Derived Factor-1 in Mesenchymal Stem Cell Paracrinemediated Tissue Repair
Current Stem Cell Research & Therapy